OpenFriend is an independent, community-built project. It is not developed, endorsed, supported, sponsored, certified, or otherwise officially connected to Microsoft Corporation, Mojang AB, Mojang ...

Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602). This is ...

aDepartment of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen ...

Forbes contributors publish independent expert analyses and insights. Kate O’Flaherty is a cybersecurity and privacy journalist. Update Dec. 13, 2024: This story, originally published Dec. 11, now ...

Apple today released iOS 18.2 and iPadOS 18.2, the second major updates to the iOS 18 and iPadOS 18 updates that came out in September. The new updates come over a month after Apple released iOS 18.1 ...

Apple has today released for download iOS 18.2 final version IPSW links and OTA profile update for iPhone. This release comes a few days after the company seeded RC2 version of iOS 18.2. If you have ...

Apple has confirmed that iOS 18.2 will roll out to iPhone users today. The update includes major new Apple Intelligence features, upgrades to the Camera Control on iPhone 16, a redesign for the Mail ...

The first iOS 18.2 developer beta has been released, and it includes a number of major changes for iPhone users. There are new Apple Intelligence features, upgrades to the Mail app, and more. Head ...

The FDA has approved Astellas’s zolbetuximab (Vyloy) for HER2-negative, claudin-18.2 (CLDN18.2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinomas. It is the first CLDN18.2-targeted ...

While the focus is currently on iOS 18 and iOS 18.1, Apple is already working on iOS 18.2 as well, and the update is expected to include several new features. Below, we recap everything that we know ...

Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met–targeting antibody-drug conjugate, in select advanced solid tumor indications. This is an ASCO Meeting Abstract from the 2024 ...